Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viatris reports robust 2022 performance, eyes growth through strategic initiatives

Viatris showcased strong financial performance and strategic execution in 2022, with a focus on integration and debt reduction post-merger.
The company's emphasis on capital allocation, product launches, and market expansion highlights a balanced approach to growth and shareholder returns.
Challenges lie in effective debt management, successful product launches, and balancing R&D investments with capital returns for optimal growth.
Overall, Viatris remains poised for growth with opportunities in new product launches, market expansion, and revenue diversification in 2023.

Viatris reports robust Q1 earnings, eyes growth in key markets

Viatris delivered strong Q1 financial performance, reaffirmed 2023 guidance, and expressed confidence in strategic plan execution.
The company's focus on key therapeutic areas, successful acquisitions, and product developments position it for growth.
While facing challenges in base business erosion and market dynamics, Viatris is exploring opportunities in new products and strategic acquisitions for future growth.

Viatris reports robust Q2 earnings, eyes strategic divestitures for growth

Viatris (VTRS) had a strong Q2 2023, reaffirming guidance, showcasing revenue growth in key markets, and addressing analyst inquiries on tax structures and market impacts. The company's focus on strategic divestitures and therapeutic verticals presents growth opportunities amidst challenges in pricing and market dynamics.

Viatris reports robust Q3 results, navigates challenges for future growth

Viatris' Q3 performance reflects strong operational results, strategic divestitures, and a focus on shareholder value creation amidst challenges from FX and inflation.
The company's financial resilience, commitment to growth, and effective cost management underscore its ability to navigate market dynamics and drive long-term success.
With a solid foundation in place, Viatris remains well-positioned to capitalize on growth opportunities, drive innovation, and deliver value to shareholders.

Viatris reports strong 2023 performance and eyes transformational 2024

Viatris had a strong 2023 and anticipates a transformational 2024 with strategic investments and capital return to shareholders.
The company's collaboration with Idorsia for exclusive global rights to assets offers significant revenue growth potential and pipeline expansion.
Despite challenges like portfolio rationalization and FTC inquiry impact, Viatris is optimistic about future growth and product launches.

Viatris reports robust Q1 performance and charts growth opportunities

Viatris delivered strong financial performance, reaffirmed guidance, and introduced new revenue projections, showcasing stability and growth potential.
While facing divestiture challenges, the company's strategic initiatives, leadership additions, and pipeline progress position it for future success.
Opportunities for revenue growth, shareholder value enhancement, and innovation highlight Viatris' path towards sustained growth and market leadership.

Viatris excels in Q3 earnings, eyes growth through innovation

Viatris demonstrated strong financial performance in Q3 2024, showcasing revenue growth, debt repayment, and strategic investments. While facing challenges in Q4, the company remains committed to enhancing shareholder value and driving innovation. By leveraging its strengths and addressing key challenges, Viatris aims to seize growth opportunities and deliver long-term value to investors.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viatris Inc. (NASDAQ: VTRS) shares have weakened from their recent highs above $18 registered in February 2021, and the current price stands around $15. Viatris reported its second-quarter results yesterday and further raised the outlook for the 2021 fiscal year.

Should you invest in Viatris Shares after strong Q2 performance?

Viatris Inc. (VTRS) CEO Michael Goettler on Q2 2021 Results - Earnings Call Transcript

Viatris (VTRS) beats on Q2 earnings and sales. The company raises annual guidance.

Viatris (VTRS) Beats on Q2 Earnings & Sales, Raises View

PITTSBURGH, Aug. 9, 2021 /PRNewswire/ --  Reports Second Quarter 2021 Financial Results - Total Revenues of $4.58 billion, U.S. GAAP Net Loss of $279 million, Adjusted EBITDA of $1.68 billion, U.S. GAAP Net Cash Provided by Operating Activities of $559 million, Free Cash Flow of $470 million Updates 2021 Financial Guidance (1) - Raises Total Revenues Guidance Range to $17.5 billion to $17.9 billion from $17.2 billion to $17.8 billion, Raises Adjusted EBITDA Guidance Range to $6.15 billion to $6.45 billion from $6.0 billion to $6.4 billion, Raises Free Cash Flow Guidance Range to $2.2 billion to $2.4 billion from $2.0 billion to $2.3 billion Announces Board of Directors Declares Quarterly Dividend of Eleven Cents ($0.11) per Share Pays Down $1.15 billion of Debt in First Half of 2021 Receives Historic Approval for First Interchangeable Biosimilar in the U.S. for Semglee® for the Treatment of Diabetes in July (substitutable for the reference product, Lantus®) (1) Viatris is not providing forward-looking guidance for U.S. GAAP net (loss) earnings or a quantitative reconciliation of its 2021 adjusted EBITDA guidance. U.S. GAAP net cash provided by operating activities for 2021 is estimated to be between $2.80 billion and $2.95 billion.

Viatris Reports Strong Second Quarter Results

Here's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former.

How This Historic FDA Approval Benefits Viatris

Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.

Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?

Viatris (VTRS) closed at $14.07 in the latest trading session, marking a -1.57% move from the prior day.

Viatris (VTRS) Dips More Than Broader Markets: What You Should Know

Bioline RX

BioNTech SE

Canadian Solar

Danaos

Global Ship Lease

Jumia

Goldman Sachs JUST US Large Cap Equity ETF

Lithium Americas Corp

Pfizer

VanEck Rare Earth/Strategic Metals ETF

SSR Mining

Universal Insurance Hlds

Zogenix

Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.

2021 Top Idea Contest - New Ideas

Sanofi

Shares of Viatris Inc. gained 3.3% in premarket trading on Thursday, the day after the Food and Drug Administration approved the first biosimilar verson of insulin glargine from Viatris and Biocon Biologics Ltd. Biocon is a privately held biopharma company based in India.

Viatris gets FDA approval of first biosimilar version of Sanofi's insulin Lantus

The FDA cleared Viatris inc (NASDAQ: VTRS) - Biocon Biologics' Semglee insulin glargine-yfgn injection as a biosimilar. Semglee indicates controlling high blood sugar in adults with type 2 diabetes and pediatric patients with type 1 diabetes.

Viatris Stock Gains After FDA Approves Viatris-Biocon Biologics' Insulin Glargine Biosimilar Injection

PITTSBURGH and BENGALURU, India, July 28, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.

Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes

Short-term uncertainties mask Viatris's long-term upside potential. This stock looks good. Shares have 40% upside today and become even more attractive as the price drops.

The Real Value Of Viatris Stock

PITTSBURGH, July 27, 2021 /PRNewswire/ -- Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas granted Mylan's motion to dismiss in a lawsuit brought against it and Pfizer by KPH Healthcare Services, Inc. (KPH) on behalf of an asserted class of direct purchasers of EpiPen® products. The court agreed with the company's argument that KPH lacked the legal standing to assert the claims in its lawsuit and dismissed the case in its entirety with an option for KPH to file a limited amended complaint within 30 days.

Mylan Wins Dismissal of Kansas EpiPen® Direct Purchaser Case

Maybe the market is about to crash, and maybe it isn't. These stocks look like good picks either way.

3 Stocks to Buy Whether or Not a Market Crash Is Near

Citigroup

J. M. Smucker

The S&P 500 continues to hit record highs. At the time of this article, the S&P 500 finished at nearly 4,375.

Bert's Dividend Stock Watch List: July 2021

Alibaba

Enterprise Products Partners

The market is 31% historically overvalued, meaning future returns for index investors are likely to be very disappointing, about 4.5% over the next five years. But even in market bubbles, anti-bubble blue-chip bargains are always available if you know where to look.

My Oh My, 3 Very Strong Buys

PITTSBURGH, July 8, 2021 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) plans to release its second quarter 2021 financial results on Monday, Aug. 9, before the open of the U.S. financial markets. Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula also will host a webcast at 10 a.m.

Viatris Inc. to Release Second Quarter 2021 Financial Results on Aug. 9, 2021

Aflac

Eaton

KeyCorp

Kroger

Lockheed Martin

LyondellBasell Industries

Target

T. Rowe Price Group

Vanguard FTSE Europe ETF

Vanguard S&P 500 ETF

Vanguard High Dividend Yield ETF

Wendy's

The stock market is continuing to set records highs, closing over $4,300 heading into July 4th. In June, we (my wife and I) received a total of $3,676.63 of dividend income.

Dividend Income Summary: Lanny's June 2021 Summary

Viatris was formed out of a merger between Pfizer's Upjohn legacy brands business and Mylan, a generic and biosimilar drug manufacturer.

Viatris: Buy Signals Are So Strong It's Hard To Ignore

Ally Financial

People's United Financial

Provident Financial Services

AT&T

Verizon

Pfizer hasn't had their price move really this year.

Dividend Stock Watch List: Lanny's July 2021 Edition

Innovative Industrial Properties

NextEra Energy

Annaly Capital

These top-notch companies could put some serious income in investors' pockets.

5 Dividend Stocks to Buy Hand Over Fist for the Second Half of 2021

PITTSBURGH, June 23, 2021 /PRNewswire/ -- Viatris (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas ruled, in substantial part, in Mylan's favor on the company's summary judgment motion in the class action related to EpiPen® Auto-Injector. The company is pleased with the court's decision to dismiss all of the plaintiffs' claims under the federal RICO statute, which include claims asserted against Mylan's former CEO Heather Bresch.

Mylan Wins Significant Summary Judgment Rulings in Kansas EpiPen® Class Action

Dividend stocks have a long history of outperforming companies that don't pay a dividend.

Got $3,000? These Top-Notch Dividend Stocks Can Double Your Money

AbbVie

Bristol-Myers

And all three of them pay solid dividends.

3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market

Goldman Sachs

Viatris Inc. (VTRS) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

News for Viatris Stock (VTRS)